Evaluation of Brain and Cognitive Changes in Older Adults with MCI Taking Lithium to Prevent Alzheimer Type Dementia

患有 MCI 的老年人服用锂预防阿尔茨海默型痴呆的大脑和认知变化的评估

基本信息

项目摘要

Alzheimer’s disease (AD) is the most common cause of dementia in adults 65 years and older. Unchecked, the disease will reach epidemic proportions in the United States and worldwide by 2050, and presently, there is no intervention that has shown a clear effect on AD progression. Over the past several years, there has been increasing interest in repurposing the use of lithium for diseases involving neurodegeneration. Lithium treatment has been associated with neurogenesis in the hippocampus, up-regulation of important neurotrophic factors such as B-cell lymphoma 2 (Bcl-2) and brain-derived neurotrophic factor (BDNF), and inhibition of glycogen synthase kinase 3 (GSK-3) isoforms α and β. In particular, GSK-3α interacts with gamma-secretase playing a critical role in the conversion of amyloid precursor protein (APP) to amyloid-beta (Aβ); lithium has been shown to reduce Aβ production and memory deficits in AD transgenic mouse models. GSK-3β phosphorylates tau, a critical step in the formation of neurofibrillary tangles, and lithium has been shown to reduce tau phosphorylation in vivo and in vitro. That lithium may alter the AD trajectory is supported by numerous observational reports showing delay of dementia onset in those treated with it. However, the results of the few human lithium trials conducted have been mixed. Additional research is needed to determine whether lithium has a role as an anti-dementia agent. In contrast to previous studies, we will implement an RCT with a more integrative, comprehensive approach than done before involving state-of-the-art ultra-high field (7T) human MRI, neurocognitive assessment, and blood- and CSF- based biomarker measurement to investigate the role of lithium as an anti-dementia agent. The specific aim of this pilot-feasibility study is to examine the potential disease modifying properties of lithium in individuals with mild cognitive impairment (MCI) in delaying conversion to dementia. The study will enroll and randomly assign 80 individuals 60 years and older with MCI (amnestic type, single or multiple domain) to take lithium, titrated to a maximally tolerated blood level (0.5 to 0.8 meq/L), or placebo for two years to assess lithium’s effects on preserving cognition and delaying conversion to dementia. Participants will receive annual neurocognitive assessment, blood- and CSF-based biomarker measurement, and 7T MR imaging of structural brain volumes (e.g., hippocampal, total cortical gray). At baseline, all subjects will undergo PET imaging for Aβ. The following hypotheses will be tested: H1: a) Participants randomized to take lithium for two years, compared to placebo, will better maintain cognitive function, primarily in memory, which b) will be associated with changes in biomarkers (e.g., GSK-3β, BDNF). H2: a) Participants randomized to take lithium, compared to placebo, will have larger hippocampal volumes and lower total gray matter thinning, which b) will be associated with changes in biomarkers and c) better cognitive function, primarily in memory. The exploratory aim examines whether lithium is related to additional markers of enhanced brain integrity (e.g., lower level of microbleeds, higher white matter integrity, better network connectivity, or decreased CSF phospho tau levels).
阿尔茨海默病(AD)是65岁及以上成年人中最常见的痴呆症原因。未选中时, 到2050年,疾病将在美国和世界范围内达到流行比例,目前还没有 干预已显示出对AD进展的明显效果。在过去的几年里,有 越来越多的人对锂在涉及神经退行性疾病的疾病中的用途进行再利用。锂治疗 与海马区的神经发生有关,上调重要的神经营养因子 作为B细胞淋巴瘤2(Bcl2)和脑源性神经营养因子(BDNF)和糖原合成酶的抑制 蛋白激酶3(GSK-3)是α和β的异构体。尤其是gsk-3α与伽马分泌酶的相互作用起着至关重要的作用。 在淀粉样前体蛋白(APP)向淀粉样β蛋白(Aβ)的转化中;锂被证明可以减少Aβ AD转基因小鼠模型的生产和记忆缺陷。葛兰素史克-3β磷酸化tau,这是 体内和体内研究表明,神经纤维缠结的形成和锂可以减少tau的磷酸化。 体外培养。锂可能改变AD轨迹的说法得到了大量观测报告的支持,这些报告表明锂可能会延迟 那些接受治疗的人会出现痴呆症。然而,进行的少数几项人体锂试验的结果是 好坏参半。还需要进一步的研究来确定锂是否具有抗痴呆剂的作用。在……里面 与以前的研究相比,我们将以更综合、更全面的方法实施RCT 在涉及最先进的超高场(7T)人体核磁共振、神经认知评估和血液- 和基于脑脊液的生物标记物测量,以研究锂作为抗痴呆剂的作用。具体的 这项试验性可行性研究的目的是检查锂在个体中潜在的疾病改善特性。 轻度认知障碍(MCI)可延缓转化为痴呆症。这项研究将随机报名 分配80名60岁及以上MCI(遗忘型、单或多个域)的人服用锂, 滴定到最大耐受血液水平(0.5meq/L)或安慰剂两年以评估锂的效果 关于保护认知和延缓转化为痴呆症。参与者将获得年度神经认知 脑结构体积的评估、基于血液和脑脊液的生物标记物测量和7T磁共振成像 (例如,海马区,总皮质灰质)。在基线时,所有受试者都将接受Aβ的正电子发射计算机断层扫描。以下是 假设将被检验:H1:A)参与者被随机服用锂两年,与安慰剂相比, 将更好地维持认知功能,主要是在记忆中,这将与 生物标志物(例如,葛兰素史克-3β、脑源性神经营养因子)。H2:a)与安慰剂相比,随机服用锂的参与者将 有更大的海马体体积和较低的总灰质变薄,这将与变化有关 生物标志物和c)更好的认知功能,主要是记忆。探索性的目标是检查锂是否 与增强大脑完整性的其他标志有关(例如,较低水平的微出血,较高的脑白质 完整性、更好的网络连通性或降低的脑脊液磷酸化tau水平)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ariel Gerard Gildengers其他文献

Ariel Gerard Gildengers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ariel Gerard Gildengers', 18)}}的其他基金

Evaluation of Brain and Cognitive Changes in Older Adults with MCI Taking Lithium to Prevent Alzheimer Type Dementia
患有 MCI 的老年人服用锂预防阿尔茨海默型痴呆的大脑和认知变化的评估
  • 批准号:
    10488908
  • 财政年份:
    2017
  • 资助金额:
    $ 72.81万
  • 项目类别:
Evaluation of Brain and Cognitive Changes in Older Adults with MCI Taking Lithium to Prevent Alzheimer Type Dementia
患有 MCI 的老年人服用锂预防阿尔茨海默型痴呆的大脑和认知变化的评估
  • 批准号:
    10192622
  • 财政年份:
    2017
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effects of Bipolar Disorder and its Comorbidities on Cognition in Older Adult
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    7789743
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effect of Bipolar Disorder and its Comorbidities on Cognition in Older Adults
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    8408809
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effects of Bipolar Disorder and its Comorbidities on Cognition in Older Adult
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    8597964
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effects of Bipolar Disorder and its Comorbidities on Cognition in Older Adult
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    8010185
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effects of Bipolar Disorder and its Comorbidities on Cognition in Older Adult
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    8207196
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
The Effects of Bipolar Disorder and its Comorbidities on Cognition in Older Adult
双相情感障碍及其合并症对老年人认知的影响
  • 批准号:
    8290604
  • 财政年份:
    2010
  • 资助金额:
    $ 72.81万
  • 项目类别:
Cognition in Euthymic Older Adults with Bipolar Disorder
患有双相情感障碍的情绪正常的老年人的认知
  • 批准号:
    6905231
  • 财政年份:
    2005
  • 资助金额:
    $ 72.81万
  • 项目类别:
Cognition in Euthymic Older Adults with Bipolar Disorder
患有双相情感障碍的情绪正常的老年人的认知
  • 批准号:
    7579753
  • 财政年份:
    2005
  • 资助金额:
    $ 72.81万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 72.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了